|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2010-11-2
|
|
pubmed:abstractText |
This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5312-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20959407-Adult,
pubmed-meshheading:20959407-Aged,
pubmed-meshheading:20959407-Aged, 80 and over,
pubmed-meshheading:20959407-Carcinoma, Renal Cell,
pubmed-meshheading:20959407-Dose-Response Relationship, Drug,
pubmed-meshheading:20959407-Female,
pubmed-meshheading:20959407-Humans,
pubmed-meshheading:20959407-Injections, Subcutaneous,
pubmed-meshheading:20959407-Interleukins,
pubmed-meshheading:20959407-Kidney Neoplasms,
pubmed-meshheading:20959407-Male,
pubmed-meshheading:20959407-Maximum Tolerated Dose,
pubmed-meshheading:20959407-Melanoma,
pubmed-meshheading:20959407-Middle Aged,
pubmed-meshheading:20959407-Neoplasm Metastasis,
pubmed-meshheading:20959407-Recombinant Proteins,
pubmed-meshheading:20959407-Skin Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
|
|
pubmed:affiliation |
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. henrschm@rm.dk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
